Gilead Sciences (GILD) announces a deal to purchase Pharmasset (VRUS) for $11B in a deal that is...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead Sciences (GILD) announces a deal to purchase Pharmasset (VRUS) for $11B in a deal that is expected to close in Q1 and become accretive to Gilead's earnings starting in 2015. The $137/share offer price agreed upon by the firms marks an 89% premium to the closing price of Pharmasset on Friday.